GlassScriptPhysician profile
Vineeta Sood
NPI 1215120183
$1,680.18
in general payments reported to CMS, 2019-2025
15 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.88 · 2020: $32.52 · 2021: $135 · 2022: $71.75 · 2023: $157 · 2024: $670 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.43 |
| Education | $103.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $561.26 | 2020-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $304.52 | 2024-2025 | |
| Vifor Pharma, INC. | $201.21 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $138.70 | 2024-2025 | Vafseo |
| Fresenius USA Marketing, INC. | $90.23 | 2024-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.82 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $58.49 | 2025 | |
| Medtronic, INC. | $57.57 | 2021 | |
| Aurinia Pharma U.S., INC. | $50.85 | 2025 | Lupkynis |
| Ardelyx, INC. | $42.16 | 2024 | Ibsrela |
| Opko Pharmaceuticals, LLC | $38.80 | 2024 | Rayaldee |
| Novo Nordisk INC | $19.62 | 2025 | Wegovy |
| Scpharmaceuticals INC. | $17.97 | 2025 | |
| Glaxosmithkline, LLC. | $17.92 | 2025 | Benlysta |
| Cormedix INC. | $16.06 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineeta Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.